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Abstract
Background: Chronic inflammation is well known to be a risk factor for colon cancer. Previously
we established a novel mouse model of inflammation-related colon carcinogenesis, which is useful
to examine the involvement of inflammation in colon carcinogenesis. To shed light on the
alterations in global gene expression in the background of inflammation-related colon cancer and
gain further insights into the molecular mechanisms underlying inflammation-related colon
carcinogenesis, we conducted a comprehensive DNA microarray analysis using our model.
Methods: Male ICR mice were given a single ip injection of azoxymethane (AOM, 10 mg/kg body
weight), followed by the addition of 2% (w/v) dextran sodium sulfate (DSS) to their drinking water
for 7 days, starting 1 week after the AOM injection. We performed DNA microarray analysis
(Affymetrix GeneChip) on non-tumorous mucosa obtained from mice that received AOM/DSS,
AOM alone, and DSS alone, and untreated mice at wks 5 and 10.
Results: Markedly up-regulated genes in the colonic mucosa given AOM/DSS at wk 5 or 10
included Wnt inhibitory factor 1 (Wif1, 48.5-fold increase at wk 5 and 5.7-fold increase at wk 10)
and plasminogen activator, tissue (Plat, 48.5-fold increase at wk 5), myelocytomatosis oncogene
(Myc, 3.0-fold increase at wk 5), and phospholipase A2, group IIA (platelets, synovial fluid) (Plscr2,
8.0-fold increase at wk 10). The notable down-regulated genes in the colonic mucosa of mice
treated with AOM/DSS were the peroxisome proliferator activated receptor binding protein
(Pparbp, 0.06-fold decrease at wk 10) and the transforming growth factor, beta 3 (Tgfb3, 0.14-fold
decrease at wk 10). The inflammation-related gene, peroxisome proliferator activated receptor γ
(Pparγ 0.38-fold decrease at wk 5), was also down-regulated in the colonic mucosa of mice that
received AOM/DSS.
Conclusion: This is the first report describing global gene expression analysis of an AOM/DSS-
induced mouse colon carcinogenesis model, and our findings provide new insights into the
mechanisms of inflammation-related colon carcinogenesis and the establishment of novel therapies
and preventative strategies against carcinogenesis.
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Background
The development and progression of colon carcinogenesis
in both humans and rodents are known to be caused by
the accumulation of cancer-related gene alterations,
which results in their altered expression. Such genes
include oncogenes, tumor suppressor genes, and mis-
match repair genes [1,2]. These changes could affect the
expression of a variety of downstream genes such as those
involved in the cell cycle, apoptosis, adhesion, and angio-
genesis [3]. Although both sporadic colorectal cancer
(CRC) and colitis-associated CRC share several molecular
alterations, the frequency and timing of certain key molec-
ular changes are different [4]. As for the chemically-
induced colon carcinogenesis in rodents, the β-catenin
gene is frequently mutated in adenocarcinomas induced
by colonic carcinogens, azoxymethane (AOM) and 2-
amino-1-methyl-6-phenylimidazo [4,5-b]-pyridine
(PhIP) in rodents [2]. The immunohistochemical expres-
sion of inducible nitric oxide synthase (iNOS), cyclooxy-
genase (COX)-2, and β-catenin is markedly elevated in the
AOM-induced CRC in rats [2].
In our recent series of studies on inflammation-related
mouse colon carcinogenesis, where mice received a single
dose of different colonic carcinogens, i.e., AOM, PhIP,
and 1,2-dimethylhydrazine, followed by one week of
exposure to 2% dextran sodium sulfate (DSS) in drinking
water, numerous CRCs developed within 20 weeks [5-7].
We also observed different sensitivities to AOM/DSS-
induced colon carcinogenesis among 4 different strains
(Balb/c, C3H/HeN, C57BL/6N, and DBA/2N) of mice [8].
Furthermore, numerous colonic tumors developed within
5 weeks in male and female ApcMin/+ mice, which contain
a truncating mutation in the Apc gene, when they received
DSS in drinking water for 7 days [9]. Molecular analysis
revealed a high-incidence (79–100%) of β-catenin gene
mutations in induced colonic adenocarcinomas [6,7].
However, there were no mutations in the colonic adeno-
carcinomas developed in the ApcMin/+ mice receiving DSS
[9]. We therefore hypothesize that a powerful tumor-pro-
motion effect of DSS is due to DSS-induced inflammatory
stimuli, especially iNOS expression, since the incidence
and multiplicity of these CRCs correlated with the
increased inflammation score and elevated iNOS expres-
sion [5-7].
Microarray technology is a powerful tool to determine
simultaneously the expression profile of numerous genes
and is rapidly becoming a standard technique, which can
be used in research laboratories across the world [10,11].
The introduction of microarray techniques has dramatic
implications on cancer research, since it allows analysis of
the expression of multiple genes in concert and helps find
reliable clinical parameters for cancer occurrence. Several
recent large-scale studies of gene expression using micro-
arrays could thus provide useful information of inflam-
matory bowel disease (IBD) and colon carcinogenesis
[12-14].
In the current study, we conducted global gene expression
analysis of the non-neoplastic (inflamed) colonic mucosa
of mice treated with AOM/DSS, AOM alone or DSS alone,
and untreated mice utilizing Affymetrix GeneChip analy-
sis in order to identify the molecular events in the back-
ground of AOM/DSS-induced mouse colon
carcinogenesis. Using our model [5], gene expression
analysis was done at wks 5 and 10 of the experimental
period, i.e. when a few precursor lesions for colonic aden-
ocarcinoma develop [15].
Methods
Animals, chemicals and diets
Male Crj: CD-1 (ICR) mice (Charles River Japan, Inc.,
Tokyo) aged 5 weeks were used. A colonic carcinogen,
AOM, was purchased from the Sigma-Aldrich Co. (St.
Louis, MO, USA). DSS with a molecular weight of
36,000–50,000 was purchased from MP Biochemicals,
LLC (Cat. no. 160110, Aurora, OH, USA). DSS for the
induction of colitis was dissolved in distilled water at 2%
(w/v). Pelleted CRF-1 (Oriental Yeast Co., Ltd., Tokyo,
Japan) was used as the basal diet throughout the study.
Experimental procedure
A total of 40 mice were acclimated for 7 days with tap
water and basal diet, CRF-1, ad libitum. The mice were
divided into 4 groups, i.e., the AOM/DSS (10 mice, Figure
1), AOM alone (10 mice), DSS alone (10 mice), and
untreated controls (10 mice). Five mice were analyzed at
each time-point. In the AOM/DSS group, mice received a
single i.p. injection of AOM (10 mg/kg body weight).
Starting 1 week after the AOM injection, they were given
2% DSS in the drinking water for 7 days, without any fur-
ther treatment until the end of the experiment. The AOM
alone group was given a single i.p. injection of AOM (10
mg/kg body weight), and no further treatment. The DSS
alone group was given 2% DSS in drinking water for 7
days (from wk 1 to wk 2), and was then maintained on
basal diet and tap water. The untreated control group was
maintained on basal diet and tap water throughout the
experiment. All mice were maintained under the control-
led conditions of humidity (50 ± 10%), light (12/12 h
light/dark cycle), and temperature (23 ± 2°C) at
Kanazawa Medical University Animal Facility according to
the Institutional Animal Care Guidelines, and were killed
by ether overdose at wks 5 and 10.
Histopathological analysis
At autopsy, the large bowel was cut open longitudinally
along the main axis, and washed with saline. After careful
macroscopic inspection, the distal colon (0.5 cm from theBMC Cancer 2007, 7:84 http://www.biomedcentral.com/1471-2407/7/84
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anus) was cut and processed for histopathological exami-
nation after hematoxylin and eosin-staining. The remain-
ing pieces of the colonic mucosa free from tumors and
large ulcers was scraped for the microarray expression
analysis.
GeneChip analysis
Scraped colonic mucosa from each treated or untreated
mice sacrificed at wks 5 and 10 were used for the Gene-
Chip analysis. Microarray expression analysis was per-
formed using a high-density oligonucleotide array
(Affymetrix GeneChip array, Affymetrix, Santa Clara, CA,
USA), and microarray expression analysis was done
according to the instruction manual. In this study, 5 Gene-
Chip array sets, corresponding to each mouse, were used
for the individual time-points. The extraction of total
mRNA from frozen colonic mucosa was done using TRI-
zol (Invitrogen Corporation, CA, USA). mRNA obtained
from 5 mice at each time-point was hybridized to each
array. Subsequently, the quality of RNA was evaluated
using an Agilent 2100 Bioanalyzer (Agilent Technologies,
Inc., Palo Alto, CA, USA), each RNA sample was converted
into double-stranded cDNA by M-MLV ReverseTran-
scriptase (RNase H free) (TAKARA BIO Inc., Shiga, Japan)
using GeneChip T7-Oligo(dT) Promoter Primer Kit.
(Affymetrix, Santa Clara, CA, USA). Double-stranded
cDNA was converted into double-stranded cRNA and
biotinylated using GeneChip Expression 3'-Amplification
Reagents for IVT labeling kit (Affymetrix). Biotin-labeled
cRNA was purified by the GeneChip Sample Cleanup
Module kit (Affymetrix) and fragmented. Hybridization
of biotin-labeled cRNA fragment to Mouse Genome 430
2.0 array, washing, staining with streptavidin-phycoeryth-
rin (Molecular Probes), and signal-amplification were
performed according to the manufacturer's instructions.
Mouse Genome 430 2.0 array has 45,000 probe sets for
analyzing the expression of 39,000 transcripts and vari-
ants from over 34,000 well characterized mouse genes.
Each hybridized Affymetrix GeneChip® array was scanned
with a GeneChip Scanner 3,000 and analyzed with the
GeneChip Operating Software package version 1.2
(Affymetrix). We analyzed 40 array data sets (n = 5 for
each time-point) to search for genes whose expression lev-
els were altered among the groups. The average hybridiza-
tion intensity for each array was determined using the
Tukey's Biweight Estimate method. Prior to statistical
analysis, 45,102 microarray data in each sample were
identified both "Present" for Detection Call or "Increase"
for Change Call based on a software analysis. The signal
intensity of all array data sets at each time-point was com-
pared among the groups, and the genes, which were dif-
ferently expressed between the treatment and untreated
groups at > 2-fold or < 1/2-fold, were selected for Venn
diagrams. In addition, we used the significance analysis of
microarrays (SAM) [16] method to identify differentially
expressed genes in the treated and untreated groups. Sig-
nificant regulation was defined as a fold change between
the treatment and untreated control groups greater than 3
or less than 1/3. SAM that uses modified t test statistics for
each gene of a dataset is a statistical technique for the find-
ing of significant genes in a set of microarray experiments.
SAM uses repeated permutations of the data to determine
if the expression of any gene is significantly related to the
response variable. A small fudge factor is added to the
denominator in calculating the t value, thereby control-
ling for unrealistically low standard deviations in the
tested gene. Furthermore, SAM allows control of the false
discovery rate (FDR) [17] by setting a threshold to the dif-
ference between the actual test result and the result from
repeated permutations of the tested groups. Thus, for
genes called significant, SAM can estimate the percentage
of genes identified by chance, FDR.
Results
Histopathology of the distal colon
Histopathological examination on the colonic mucosa
revealed a few of spotted mucosal ulcers with regenerative
changes in the AOM/DSS and DSS groups, but not in the
AOM alone and untreated groups (Figure 2).
Gene expression profile
The numbers of up- (> 2-fold) or down- (< 1/2-fold) reg-
ulated genes in the colonic mucosa of mice were noted at
the 2 time-points, as shown in the Venn diagrams (Figure
3). At wk 5, the number of up (180 genes)- or down (459
genes)-regulated genes in the AOM alone group was
smaller than that of the DSS alone (1270 up- and 1280
down-regulated genes) and the AOM/DSS treated groups
(1327 up- and 1307 down-regulated genes). Similarly, at
wk 10 genes with altered expression in the AOM alone
group (229 up- and 189 down-regulated genes) was much
less than in comparison the 2 other groups (688 up- and
1465 down-regulated genes in the AOM/DSS group; and,
802 up- and 1399 down-regulated genes in the DSS alone
group). The numbers of over- or under-expressed genes
(611 up- and 507 down-regulated genes at wk 5; and 412
up- and 1107 down-regulated genes at wk 10), which
were found in both the DSS alone and AOM/DSS groups
at the 2 two time-points, were greater than that detected in
both the AOM alone and AOM/DSS-treated groups (89
Experimental protocol for the AOM/DSS group Figure 1
Experimental protocol for the AOM/DSS group.BMC Cancer 2007, 7:84 http://www.biomedcentral.com/1471-2407/7/84
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up- and 186 down-regulated genes at wk 5; and 104 up-
and 87 down-regulated genes at wk 10). Regarding the
AOM/DSS group, the number of genes (675 up-regulated;
and 703 down-regulated) with altered expression at wk 5
was greater than that found at wk 10 (263 up-regulated;
and 343 down-regulated).
Up-regulated genes in the AOM/DSS group
Among the > 2-fold up-regulated genes in the AOM/DSS
group (Figure 3A and 3B), 163 and 35 genes were signifi-
cantly elevated by > 3-fold at wks 5 and 10, respectively.
Among them, the genes whose functions are known are
listed in Tables 1 and 2. The expression of Wnt inhibitory
factor 1 (Wif1) and plasminogen activator, tissue (Plat)
was up-regulated by 48.5-fold at wk 5 (Table 1). In addi-
tion, myelocytomatosis oncogene (Myc), matrix metallo-
proteinase 2 (Mmp2) and 14 (Mmp14) were significantly
up-regulated by 3.0~ 4.0-fold at wk 5. However, at wk 10,
phospholipase A2, group IIA (platelets, synovial fluid)
(Plscr2), which plays a key role in the production of pro-
inflammatory mediators, was significantly up-regulated
by 8.0-fold (Table 2). Axin 2, T-box 3 (Tbx3), chloride
channel calcium activated 1 /// Chloride channel calcium
activated 2 (Clca1 /// Clca2), and Wif1 were also signifi-
cantly up-regulated by 3.0~ 48.5-fold at wks 5 and 10
(Tables 1 and 2).
Down-regulated gense in the AOM/DSS group
Among the down-regulated genes by < 1/2-fold in the
AOM/DSS group (Figure 3C), 114 genes were significantly
down-regulated by < 1/3-fold at wk 5. The genes with
known functions are listed in Table 3. Genes associated
with the transport, regulation of transcription, and prote-
olysis and peptidolysis were suppressed. At wk 10, among
the genes that were < 1/2-fold (Figure 3D), 6 genes with
known functions were significantly down-regulated by <
1/3-fold in the AOM/DSS group (Table 4). The gene with
markedly less expression was peroxisome proliferator acti-
vated receptor binding protein (Pparbp), which is co-acti-
vator of peroxisome proliferator activated receptor (Ppar).
Expression of inflammation-related genes
The expression of inflammation-related genes was evalu-
ated utilizing the Chip data (data not shown). At wk 5 or
10, tumor necrosis factor receptor superfamily, member
1b (Tnfrsf1b), interferon gamma inducible protein 47
(Ifi47), tumor necrosis factor, alpha-induced protein 9
(Tnfaip9), interferon gamma induced GTPase (Igtp),
chemokine (C-C motif) receptor 1 (Ccr1), prostaglandin
D2 synthase 2, hematopoietic (Ptgds2), transforming
growth factor, beta 1 (Tgfb1), and toll-like receptor 2
(Tlr2) were up-regulated by > 2-fold in the AOM/DSS
group compared to the untreated controls. In addition,
transforming growth factor, beta 3 (Tgfb3) and peroxi-
some proliferator activated receptor γ (Pparγ) in the AOM/
Histopathology of colonic mucosa Figure 2
Histopathology of colonic mucosa. Colon from mice that received (A) AOM and 2%BMC Cancer 2007, 7:84 http://www.biomedcentral.com/1471-2407/7/84
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Venn diagrams Figure 3
Venn diagrams. The numbers of up-regulated genes at wk 5 (A) and wk 10 (B), and down-regulated genes at wk 5 (C) and at 
wk 10 (D) in the colonic mucosa of mice in the AOM alone, DSS alone, and AOM/DSS groups. The numbers indicate the num-
bers of genes with their expression by over 2-fold up-regulated or by less 1/2-fold down-regulated between the treated (AOM-
, DSS- or AOM/DSS) groups and untreated control group.
Table 4: The down-regulated genes by less than 1/3-fold in the AOM/DSS group at wk 10
Gene name (gene symbol) Average fold of change (AOM/DSS vs. untreated)
RIKEN cDNA 1110033J19 gene 0.05
Peroxisome proliferator activated receptor binding protein (Pparbp) 0.06
Serine/threonine kinase 25 (yeast) (Stk25) 0.09
Transforming growth factor, beta3 (Tgfb3) 0.14
Cytochrome P450, family 3, subfamily a, polypeptide 13 (Cyp3a13) 0.31
APG4 (ATG4) autophagy-related homolog A (S. cerevisiae) (Apg4a) 0.33
Pleckstrin homology domain interacting protein (Phip) 0.33BMC Cancer 2007, 7:84 http://www.biomedcentral.com/1471-2407/7/84
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Table 1: The up-regulated genes by over 3-fold in the AOM/DSS group at wk 5
Gene name (gene symbol) Average fold of change 
(AOM/DSS vs. untreated)
Plasminogen activator, tissue (Plat)4 8 . 5
Wnt inhibitory factor 1 (Wif1)4 8 . 5
Metallothionein 3 (Mt3) 11.3
Chloride channel calcium activated 1 /// chloride channel calcium activated 2 (Clca1 /// Clca2)9 . 2
Nuclear factor, erythroid derived 2, like 3 (Nfe2l3)7 . 5
Protein tyrosine phosphatase, receptor type, O (Ptpro)7 . 5
Transient receptor potential cation channel, subfamily V, member 6 (Trpv6)7
Chloride channel calcium activated 2 (Clca2)7
Dual specificity phosphatase 4 (Dusp4)5 . 7
Heat shock protein 1 (Hspb1)5 . 7
Advillin (Avil) 5.3
Proprotein convertase subtilisin/kexin type 9 (Pcsk9)4 . 9
Extracellular matrix protein 1 (Ecm1)4 . 9
Bone morphogenetic protein 4 (Bmp4)4 . 6
Insulin-like growth factor binding protein 3 (Igfbp3)4 . 3
Axin2 (Axin2) 4.3
Transferring (Trf) 4.3
Caldesmon 1 (Cald1) 4.3
Guanylate nucleotide binding protein 2 (Gbp2)4 . 3
Gap junction membrane channel protein alpha 1 (Gja1)4 . 3
WASP family 1 (Wasf1) 4
Aspartoacylase (aminoacylase) 2 (Aspa)4
Notch gene homolog 4 (Drosophila) (Notch4)4
Matrix metalloproteinase 2 (Mmp2)4
Actin, alpha 2, smooth muscle, aorta (Acta2)4
Transgelin (Tagln) 4
Dermatopontin (Dpt) 4
Integrin alpha X (Itgax) 4
Hedgehog-interacting protein (Hhip)4
Latent transforming growth factor beta binding protein 4 (Ltbp4)4
Myeloid ecotropic viral integration site-related gene 1 (Mrg1)3 . 7
Dachshund 1 (Drosophila) (Dach1)3 . 7
Membrane targeting (tandem) C2 domain containing 1 (Mtac2d1)3 . 7
Laminin B1 subunit 1 (Lamb1-1)3 . 7
RAS-related C3 botulinum substrate 3 (Rac3)3 . 7
Nitric oxide synthase 2, inducible, macrophage (Nos2)3 . 6
Bone morphogenetic protein 5 (Bmp5)3 . 5
Methylthioadenosine phosphorylase (Mtap)3 . 5
Transcription factor 4 (Tcf4)3 . 5
Transcription factor 21 (Tcf21)3 . 5
CCAAT/enhancer binding protein (C/EBP), delta (Cebpd)3 . 5
Apolipoprotein B editing complex 2 (Apobec2)3 . 5BMC Cancer 2007, 7:84 http://www.biomedcentral.com/1471-2407/7/84
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Microtubule associated serine/threonine kinase-like (Mastl)3 . 5
Carboxypeptidase X 2 (M14 family) (Cpxm2)3 . 5
Ubiquitin specific protease 18 (Usp18)3 . 5
Procollagen, type VI, alpha 2 (Col6a2)3 . 5
Chloride channel calcium activated 4 (Clca4)3 . 5
Myosin, light polypeptide 9, regulatory (Myl9)3 . 5
Small muscle protein, X-linked (Smpx)3 . 5
Glutathione peroxidase 3 (Gpx3)3 . 5
Septin 4 (4-Sep) 3.5
Cysteine rich protein 2 (Crip2)3 . 5
Fibroblast growth factor 7 (Fgf7)3 . 2
Proline arginine-rich end leucine-rich repeat (Prelp)3 . 2
Expressed sequence AW125753 /// protein tyrosine phosphatase, receptor type, J (AW125753 /// Ptprj)3 . 2
BTB (POZ) domain containing 11 (Btbd11)3 . 2
Calpain 2 (Capn2) 3.2
Transglutaminase 2, C polypeptide (Tgm2)3 . 2
Matrix metalloproteinase 14 (membrane-inserted) (Mmp14)3 . 2
SEC8-like 1 (S. cerevisiae) (Sec8l1)3 . 2
ADP-ribosylation factor 2 (Arf2)3 . 2
Calponin 3, acidic (Cnn3) 3.2
Actin, gamma 2, smooth muscle, enteric (Actg2)3 . 2
Stathmin 1 (Stmn1) 3.2
Chondroitin sulfate proteoglycan 2 (Cspg2)3 . 2
DEP domain containing 1a (Depdc1a)3 . 2
Inhibitor of DNA binding 2 (Idb2)3 . 2
Pleckstrin homology-like domain, family A, member 1 (Phlda1)3 . 2
Myelocytomatosis oncogene (Myc)3
Stabilin 1 (Stab1) 3
Guanylate cyclase 1, soluble, beta 3 (Gucy1b3)3
RNA binding motif, single stranded interacting protein 1 (Rbms1)3
RAD51 associated protein 1 (Rad51ap1)3
SRY-box containing gene 4 (Sox4)3
T-box 3 (Tbx3) 3
Kruppel-like factor 7 (ubiquitous) (Klf7)3
Bcl-2-related ovarian killer protein (Bok)3
Estrogen-related receptor beta like 1 (Esrrbl1)3
Complement component 3a receptor 1 (C3ar1)3
Tropomyosin 2, beta (Tpm2)3
Procollagen, type V, alpha 1 (Col5a1)3
Integrin alpha 8 (Itga8) 3
Annexin A8 (Anxa8) 3
Podocalyxin-like (Podxl) 3
Retinol dehydrogenase 9 (Rdh9)3
Tumor necrosis factor, alpha-induced protein 9 (Tnfaip9)3
Table 1: The up-regulated genes by over 3-fold in the AOM/DSS group at wk 5 (Continued)BMC Cancer 2007, 7:84 http://www.biomedcentral.com/1471-2407/7/84
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DSS group were down-regulated by < 1/2-fold when com-
pared with the untreated group at wk 5 or 10.
Up-regulated genes in colonic mucosa of all groups
Forty-eight and 91 genes were up-regulated ≥ 2-fold in
common in the AOM alone, DSS alone, and AOM/DSS
groups at wks 5 and 10, respectively (Figure 3A and 3B).
At wk 5, the expression of runt related transcription factor
2 (Runx2) and secreted frizzled-related sequence protein 2
(Sfrp2) were significantly up-regulated by more than 10-
fold in the AOM/DSS group. In addition, pancreatic
lipase-related protein 2 (Pnliprp2) was significantly over-
expressed in both the DSS alone and AOM/DSS groups. At
wk 10, the expression of suppressor of cytokine signaling
3 (Socs3) and interferon gamma inducible protein 47
(Ifi47) were significantly up-regulated by nearly 10-fold in
the AOM/DSS group. The genes responsible for nitrogen
metabolism and nitric oxide biosynthesis were also signif-
icantly up-regulated in the DSS alone and AOM/DSS
group at wk 10. The up-regulation of interferon-induced
protein with tetratricopeptide repeats 2 (Ifit2) was found
at wks 5 and 10.
Down-regulated gene in colonic mucosa of AOM/DSS, 
AOM alone, and DSS alone groups
The genes down-regulated by < 1/2-fold in common in
the AOM alone, DSS alone, and AOM/DSS groups at wk 5
and 10 numbered 89 and 72, respectively (Figure 3C and
3D). The genes associated with the transport and regula-
tion of transcription were down-regulated in all the treat-
ment groups at wks 5 and 10. In the AOM/DSS group,
tensin-like SH2 domain containing 1 (Tens1), ring finger
protein 25 (Rnf25), carbonic anhydrase 8 (Car8), solute
carrier family 13 (sodium/sulphate symporters), member
1 (Slc13a1), regulator of G-protein signaling 17 (Rgs17),
prolactin receptor (Prlr), and complement receptor
related protein (Crry) were significantly down-regulated at
wk 5. At wk 10, xanthine dehydrogenase (Xdh), Max
dimerization protein (Mad), protein kinase, cAMP
dependent, catalytic, beta (Prkacb), plexin A2 (Plxna2),
and 4.5 LIM domains 1 (Fhl1) in the DSS alone and AOM/
DSS groups significantly suppressed their expression in
comparison with the AOM alone group. At both wks 5
and 10, kit ligand (Kitl) showed significantly reduced
expression.
Discussion
The current investigation using GeneChip analysis dem-
onstrates the alterations in multiple genes' expression in
the colonic mucosa of mice treated with AOM and/or
DSS. Although we found an over-expression of β-catenin,
COX-2 and iNOS in the colonic neoplasms induced by
the treatment of AOM and DSS in mice in our previous
immunohistochemical studies [5-7], other numerous and
attractive gene alterations became apparent in the present
study. Interestingly, the number of genes that showed
altered expression in the colonic mucosa in mice exposed
to AOM/DSS was greater than that found in the mice
given AOM alone or DSS alone. We also revealed that the
number of genes with altered expression in the colonic
mucosa in the mice treated with AOM/DSS at wk 5 was
greater than that detected at wk 10. Our findings may sug-
Table 2: The up-regulated genes by over 3-fold in the AOM/DSS group at wk 10
Gene name (gene symbol) Average fold of change (AOM/DSS vs. untreated)
Pancreatic lipase-related protein 2 (Pnliprp2)1 4 . 9
Matrix gamma-carboxyglutamate (gla) protein (Mglap)9 . 8
Phospholipase A2, group IIA (platelets, synovial fluid) (Plscr2)8
Wnt inhibitory factor 1 (Wif1)5 . 7
Interferon induced transmembrane protein 3 (Ifitm3)4 . 3
SRY-box containing gene 17 (Sox17)4
Expressed sequence AW111922 4
T-box 3 (Tbx3)3 . 7
Interferon gamma induced GTPase (Igtp)3 . 7
EGL nine homolog 3 (C. elegans) (Egln3)3 . 5
Roundabout homolog 1 (Drosophila) (Robo1)3 . 5
Histocompatibility 2, Q region locus 1 (H2-Q1) 3.5
Glutamyl aminopeptidase (Enpep)3 . 2
Chloride channel calcium activated 1 (Clca1)3 . 2
Chloride channel calcium activated 1 /// chloride channel calcium 
activated 2 (Clca1 /// Clca2)
3.2
Defensin related sequence cryptdin peptide (paneth cells) (Defcr-rs1)3 . 2
Axin2 (Axin2)3
Fatty acid desaturase 1 (Fads1)3
ATPase, class V, type 10A (Atp10a)3
CD8 antigen, alpha chain (Cd8a)3
Tumor necrosis factor, alpha-induced protein 9 (Tnfaip9)3BMC Cancer 2007, 7:84 http://www.biomedcentral.com/1471-2407/7/84
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Table 3: The down-regulated genes by less than 1/3-fold in the AOM/DSS group at wk 5
Gene name (gene symbol) Average fold of change (AOM/DSS vs. untreated)
Solute carrier family 10, member 2 (Slc10a2) 0.12
Rho GTPase activating protein 20 (Arhgap20) 0.12
Cytochrome P450, family 2, subfamily d, polypeptide 26 (Cyp2d26) 0.13
Aldehyde dehydrogenase family 1, subfamily A1 (Aldh1a1) 0.14
Dipeptidase 1 (renal) (Dpep1) 0.15
UDP-glucuronosyltransferase 8 (Ugt8) 0.15
Dehydrogenase/reductase (SDR family) member 8 (Dhrs8) 0.15
Solute carrier family 3, member 1 (Slc3a1) 0.16
Paired-like homeodomain transcription factor 2 (Pitx2) 0.19
Glycoprotein galactosyltransferase alpha 1, 3 (Ggta1) 0.19
N-acetylglutamate synthase (Nags) 0.19
Adrenergic receptor, alpha 2a (Adra2a) 0.19
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (Hmgcs2)0 . 2
Cytochrome P450, family 4, subfamily f, polypeptide 16 (Cyp4f16)0 . 2
Glucosaminyl (N-acetyl) transferase 3, mucin type (Gcnt3)0 . 2
Glutamyl aminopeptidase (Enpep)0 . 2
Homeo box B5 (Hoxb5) 0.22
Caudal type homeo box 2 (Cdx2) 0.22
Fatty acid binding protein 2, intestinal (Fabp2) 0.22
Glutamic pyruvic transaminase 1, soluble (Gpt1) 0.22
Mitogen activated protein kinase 10 (Mapk10) 0.23
Meprin 1 alpha (Mep1a) 0.23
UDP-N-acetyl-alpha-D-galactosamine:(N-acetylneuraminyl)-
galactosylglucosylceramide-beta-1, 4-N-acetylgalactosaminyltransferase 
(Galgt1)
0.23
CD36 antigen (Cd36) 0.25
Mercaptopyruvate sulfurtransferase (Mpst) 0.25
FK506 binding protein 5 (Fkbp5) 0.27
Acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-
Coenzyme A thiolase) (Acaa2)
0.27
Histocompatibility 2, class II antigen E alpha (H2-Ea) 0.27
RAB37, member of RAS oncogene family (Rab37) 0.27
BRAF35/HDAC2 complex (Bhc80) 0.29
Protein tyrosine phosphatase, receptor type, R (Ptprr) 0.29
N-acylsphingosine amidohydrolase (alkaline ceramidase) 3 (Asah3) 0.29
Pyruvate dehydrogenase kinase, isoenzyme 4 (Pdk4) 0.31
Nuclear receptor subfamily 5, group A, member 2 (Nr5a2) 0.31
RIKEN cDNA 9030612M13 gene (9030612M13Rik) 0.31
Mitogen activated protein kinase kinase kinase 2 (Map3k2) 0.31
Angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 (Ace2) 0.31
Vanin 1 (Vnn1) 0.31
ATP-binding cassette, sub-family B (MDR/TAP), member 1A (Abcb1a) 0.31
Kinesin family member C3 (Kifc3) 0.31
3'-phosphoadenosine 5'-phosphosulfate synthase 2 (Papss2) 0.33
Cytochrome P450, family 2, subfamily c, polypeptide 55 (Cyp2c55) 0.33
Ring finger protein 130 (Rnf130) 0.33
Phosphate cytidylyltransferase 1, choline, alpha isoform (Pcyt1a) 0.33
Potassium channel, subfamily K, member 5 (Kcnk5) 0.33
Solute carrier family 9 (sodium/hydrogen exchanger), member 2 (Slc9a2) 0.33
Solute carrier family 20, member 1 (Slc20a1) 0.33
Synaptotagmin-like 4 (Sytl4) 0.33
Regulator of G-protein signaling 13 (Rgs13) 0.33
Diaphanous homolog 1 (Drosophila) (Diap1) 0.33
Fibrinogen-like protein 2 (Fgl2) 0.33
Epidermal growth factor (Egf) 0.33BMC Cancer 2007, 7:84 http://www.biomedcentral.com/1471-2407/7/84
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gest the numerous gene alterations at the early phase of
colitis-related mouse colon carcinogenesis might contrib-
ute to the development of colonic tumors at the later stage
of carcinogenesis.
The most striking change in gene expression observed was
over-expression of Wif1  (48.5-fold increase over the
untreated control) seen in the AOM/DSS group at wk 5.
The Wingless-type (Wnt) signaling pathway is known to
play a central role in CRC development [18]. Wif1 is a
secreted antagonist that can bind to Wnt proteins directly,
and thus inhibits the Wnt signaling pathway [19]. Down-
regulation of Wif1 mRNA expression is observed in
esophageal, gastric, colorectal, and pancreatic cancers
[20]. These findings in cancer tissue specimens conflict
with our results, but our findings were from colonic
mucosa without tumors. We can thus speculate that the
over-expression of Wif1 prevents the carcinogenesis proc-
ess through inactivation of Wnt signaling, since the up-
regulation of Wif1 was found in the AOM/DSS group, but
not in the AOM alone and DSS alone groups. On the other
hand, Cebrat et al. [21] suggested that Wif1 may poten-
tially be a new factor in intestinal tumorigenesis. They
reported that Wif1 is over-expressed in intestinal adeno-
mas of ApcMin/+ mice and human colon adenocarcinoma
cell lines [21]. In the present study, Wif1 is over-expressed
at wks 5 and 10. The up-regulation of Wif1 is thus one of
the important genes in this AOM/DSS-induced mouse
colon carcinogenesis. Further investigations are required
to clarify how Wif1  is involved in the inflammation-
related colon carcinogenesis. Plat was also up-regulated in
the AOM/DSS group. Although we did not determine the
degree of inflammation, the findings are in agreement
with those reported by others [22] and with our own data
[23].
One of the interesting findings is that the stress-related
genes, i.e., metallothionein (Mt) and heat shock protein
(HSP) were up-regulated. Over-expression of Mt and HSP
was in the inflamed colonic mucosa of mice and rats that
received DSS [24,25]. The Mt expression is also altered in
the early step of IBD and ulcerative colitis (UC)-associated
CRC [26]. Costello et al. [12] reported over-expression of
HSP in the colon in Crohn's disease (CD), which is
another type of IBD. Since the oxidative/nitrosative stress
caused by DSS in the colonic mucosa contributes to
colonic tumor development in our inflammation-related
mouse colon carcinogenesis model [8,9,15,23], Mt-3
might be up-regulated to protect cells from oxidative
stress [27].
In the present study, genes involving inflammation
altered their expression in the AOM/DSS group, for exam-
ple, prostaglandin-endoperoxide synthase 2 (Ptgds2),
which is one of the important mediators of colonic
inflammation [28], was up-regulated. However, the
expression of Ptgs2 did not significantly alter in the AOM/
DSS group when compared with the untreated group
between wks 5 (1.6-fold increase) and 10 (0.5-fold
increase). As for nitric oxide synthases, the expression of
nitric oxide synthase 2, inducible macrophage (NOS2),
but not NOS1 and NOS3, was up-regulated by 3.6-fold at
wk 5. Moreover, this up-regulation continued up to wk 10
(by 1.6-fold), being in line with our previous findings
[15]. Also, pancreatic lipase-related protein (pnliprp2) and
Plscr2 were over-expressed in this study. Dietary triglycer-
ides are precursors for cellular membranes and for pros-
taglandins, thromboxanes, and leukotrienes [29].
Triacylglycerols and phospholipids are hydrolyzed by
pancreatic enzymes, including pancreatic lipase and phos-
pholipase A2 (PLA2). PLA2is a rate-limiting enzyme of the
arachidonic acid cascade, and is involved in the produc-
tion of prostaglandins. In addition, PLA2influences intes-
tinal inflammation in human [13] and rodents [30].
PLA2also involves colitis-related colon carcinogenesis in
rats [31]. These genes might thus play a pivotal role in the
inflammatory processes in our mouse model used in this
study. PPARγ plays certain role in anti-inflammation [32],
colon carcinogenesis [33,34], and cancer development in
the inflamed colon [33,35]. In fact, lowered expression of
PPARγ could be a risk factor for carcinogenesis [36,37].
Therefore, down-regulated PPARγ by the combined treat-
ment of AOM and DSS in this study might partly contrib-
ute to CRC development [5,8,15,23]. In the current study,
one of the striking down-regulated genes was Pparbp,
which is identified as a coactivator for PPARγ [38]. Down-
regulated Pparbp might be partly associated with down
expression of PPARγ. Loss of transforming growth factor β
(TGF-β) signaling is considered to be an essential step in
carcinogenesis [39], and decreased TGF-β3 mRNA level is
mediated by nitric oxide [40]. Expression of cytochrome
P450 (CYP) is altered during inflammation [41]. Admin-
istration of lipopolysaccharide that causes inflammation
reduces the intestinal epithelial CYP3A [42] and hepatic
CYP2C [43] activities in rats. In the current study, CYP 3A
and 2C family (CYP, family 3, subfamily a, polypeptide
13 (Cyp3a13) and CYP, family 2, subfamily c, polypeptide
55 (Cyp2c55)) were down-regulated by the combined
treatment with AOM and DSS at wks 5 and 10. Down-reg-
ulation of CYP, family 4, subfamily f, polypeptide 16
(Cyp4f16) genes could induce inflammatory cytokines
and mediators in the colon of mice treated with AOM/
DSS, since the concentrations of leukotriene and prostag-
landin mediators are elevated by decreased CYP 4F level
[44]. Alteration of inflammatory mediators produced by
treatment with AOM/DSS may enhance or accelerate the
occurrence and progression of CRC.
The histopathological relationship between the severity of
inflammation induced by DSS and CRC development inBMC Cancer 2007, 7:84 http://www.biomedcentral.com/1471-2407/7/84
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mice is closely similar to that of UC and CRC occurrence
in humans [45,46]. Alterations of gene expression in the
colonic mucosa of mice treated with AOM/DSS were sim-
ilar to those found in the IBD. Over-expression of PAP,
Mmp 2, Mmp 14, Myc, MT, and Plscr2 was found in the
colonic mucosa of IBD patients [12,13,47-49]. EGL nine
homolog 3 (C. elegans) (Egln3) and Plat gene were also up-
regulated in the colon of UC patients [12,22]. Down-reg-
ulation of meprin 1 alpha (Mep 1a) and solute carrier fam-
ily 20, member 1 (Slc20a1) were observed in the colon of
UC [13]. Furthermore, alterations of gene expression in
interleukin 1 receptor antagonist 1 (Il1rn, 2-fold), enoyl
coenzyme A hydratase 1, peroxisomal (Ech1, 0.47-fold),
immediate early response 3 (Ler3, 3.8-fold), baculoviral
IAP repeat-containing 4 (Birc4, 0.41-fold), DnaJ (Hsp40)
homolog, subfamily B, member 5 (Dnajb5, 2.6-fold), neu-
ral precursor cell expressed, developmentally down-regu-
lated gene 9 (Nedd9, 0.44-fold), cytokine inducible SH2-
containing protein (Cish, 0.5-fold), centromere protein E
(Cenpe, 2.1-fold), and tissue inhibitor of metalloprotein-
ase 2 (Timp2, 2.1-fold) in the AOM/DSS group were simi-
lar to those found in the UC and/or CD patients
[12,13,50]. These findings may suggest that our model is
useful for a mechanistic analysis and therapeutic
approaches of IBD-related CRC.
Nuclear factor-kappaB (NF-κB) is a transcription factor
that plays a crucial role in inflammation, immunity, cell
proliferation, apoptosis, and tumorigenesis [51]. Activa-
tion of NF-κB is associated with transglutaminase 2, MT,
and tumor necrosis factor receptor [51-53], which was up-
regulated in the present study. Oxidative stress involving
in CRC development in the AOM/DSS-induced mouse-
colon carcinogenesis [8,15,23] also leads to NF-κB activa-
tion [54]. Certain genes and their products that involve in
tumorigenesis are regulated by NF-κB [51]. iNOS and
COX-2 that are up-regulated in colonic neoplasms
induced by AOM and DSS [5], might be influenced by the
activation NF-κB [51]. It is thus possible that NF-κB also
plays an important role in AOM/DSS-induced mouse
colon carcinogenesis.
Our GeneChip analysis of the gene expression in the
colonic mucosa of mice that received AOM/DSS first
revealed altered expression of multiple genes. The gene
expressional profile of the AOM/DSS group was dissimilar
to that of the AOM alone or DSS alone group. These are
the genes whose transcription was more affected by the
stimulus of AOM/DSS treatment in comparison to those
with AOM or DSS treatment alone. Our results shed fur-
ther light on the mechanisms of inflammation-related
colon carcinogenesis. The expression of several genes,
including those classified as proteolysis and peptidolysis,
cell adhesion, transport, regulation of cell growth, devel-
opment, DNA replication, and regulation of transcription
(DNA-dependent), were altered during the early phase
(wks 5–10) of AOM/DSS-induced mouse colon tumori-
genesis. Based on our results, further investigations are
underway to identify and confirm the optimal target genes
that involve in inflammation-related colon carcinogenesis
in humans as well as rodents in our laboratory.
Conclusion
Our findings by global genes' expression analysis for an
AOM/DSS-induced mouse colon carcinogenesis model
probably provide new insights into the mechanisms of
inflammation-related colon carcinogenesis and the estab-
lishment of new therapies and preventative strategies for
inflammation-related colon carcinogenesis.
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